1.Paroxysmal nocturnal hemoglobinuria with cerebral venous sinus thrombosis:a case report and literature review
Wenxian LU ; Xiaomeng DONG ; Yaozhi HU ; Jinbo CHEN
International Journal of Cerebrovascular Diseases 2015;(2):156-160
Paroxysmalnocturnalhemoglobinuria(PNH)isadefectdiseaseofacquiredclonal hematopoietic stem cel s. It can be expressed as hemolytic anemia, hemoglobinuria, and venous thrombosis. Cerebral venous sinus thrombosis (CVST) is a rare but serious complication of PNH. Here we report a PNH patient with CVST and reviewthe relevant literature. For patients who have the risk factors for CVST and neurological symptoms, such as headache and increased intracranial pressure, should early conduct brain imaging examination and make the diagnosis clear, and give an active treatment in the aspects of anticoagulation, dehydration, eliminating the causes of disease, and controling complications.
2.Predictive value of plasma copeptin level for the outcomes in patients with acute ischemic stroke
Xiangming YI ; Yuan WANG ; Yuliang WANG ; Xiaomeng DONG ; Yaozhi HU ; Jinbo CHEN
International Journal of Cerebrovascular Diseases 2015;(9):657-661
Objective To investigate the predictive value of plasma copeptin level for the outcomes in patients with acute ischemic stroke. Methods Consecutive patients with acute ischemic stroke were enroled in the study. Enzyme-linked immunosorbent assay was used to detect the plasma copeptin level. The National Institutes of Health Stroke Scale (NIHSS) was used to evaluate baseline stroke severity. The outcome was evaluated at 90 days with the modified Rankin Scale (mRS), and the good outcome was defined as mRS 0 - 2. Results A total of 160 patients with acute ischemic stroke were enroled, 121 had good outcome and 39 had poor outcome. The age (71. 87 ± 6. 11 years vs. 66. 19 ± 9. 39 years; t =- 3. 540, P = 0. 001), serum levels of C-reactive protein (6. 84 ± 2. 80 mmol/L vs. 5. 84 ± 2. 89 mmol/L;t = - 2. 459, P = 0. 023) and copeptin (143. 12 ± 34. 02 pmol/L vs. 50. 78 ± 18. 62 pmol/L; t = 21. 564, P <0. 001), NIHSS score (12. 00 ± 4. 00 vs. 6. 00 ± 3. 00; t = - 7. 861, P < 0. 001), as wel as proportions of patients with hypertension (79. 5% vs. 60. 3% ; χ2 = 4. 758, P = 0. 029), atrial fibrilation (20. 51% vs. 7. 44% ; χ2 = 4. 022, P = 0. 045), and large artery atherosclerotic stroke (43. 59% vs. 22. 31% ; χ2 = 6. 696, P = 0. 010) in the poor outcome group were significantly higher than those in the good outcome group, but diastolic blood pressure was significantly lower (89 ± 12 mmHg vs. 95 ± 9 mmHg, 1 mmHg = 0. 133 kPa;t = 3. 323, P = 0. 001). Multivariate logistic regression analysis showed that the plasma copeptin level (odds ratio 2. 332, 95% confidence interval 1. 725 - 3. 153; P < 0. 001) was an independent risk factor for the poor outcome in patients with acute ischemic stroke. Person correlation analysis showed that the plasma copeptin level and baseline NIHSS score showed a significant positive correlation (r = 0. 895, P < 0. 001). Receiver operating characteristic (ROC) analysis showed that plasma copeptin level has a significant predictive value for the poor outcome at day 90 after acute ischemic stroke (area under the ROC curve = 0. 740, 95%confidence interval 0. 623 - 0. 783; P < 0. 01). When plasma copeptin level > 104. 3 pmol/L was used as the cutoff value, the sensitivity and specificity for predicting the poor outcomes at day 90 after onset were 86. 8% and 40. 2% , respectively. Conclusions The plasma copeptin level may be a good predictor for neurological outcome at day 90 after onset in patients with acute ischemic stroke.
3.Impact of stenting at the origin of vertebral artery on cognitive function in patients with first-onset temporal or thalamic infarction
Yaozhi HU ; Shanshan CUI ; Ligong ZHANG ; Linzhi GAO
Journal of Clinical Medicine in Practice 2024;28(13):67-71
Objective To investigate the impact of stenting at the origin of vertebral artery(VAO)on cognitive function in patients with first-onset temporal or thalamic infarction.Methods A total of 65 patients with first-onset temporal or thalamic infarction were selected as research subjects,and were diagnosed with new-onset infarction in the medial temporal lobe or thalamus by craniocere-bral magnetic resonance imaging(MRI),and severe stenosis of VAO as the responsible vessel for in-farction was confirmed by head and neck computed tomography angiography(CTA).A total of 35 pa-tients who received VAO stenting were included in the stenting group,and 30 patients who received drug-based conservative treatment were included in the control group.The Montreal Cognitive Assess-ment Scale(MoCA),Wechsler Adult Intelligence Scale-Digit Span Test(WAIS-DS),and Fuld Ob-ject Memory Evaluation Scale(FOM)scores were compared between the two groups before treatment,14 days and 3 months after treatment.Results Before treatment,there was no significant difference in the scores of each scale between the two groups(P>0.05).At 14 days and 3 months after treat-ment,the total MoCA score and the scores of visual space and executive function,delayed recall,and language dimension in the stenting group were higher than those in the control group(P<0.05).The FOM score in the stenting group was higher than that in the control group at 3 months after treat-ment(P<0.05).Conclusion Stenting can significantly improve the cognitive function of patients with temporal lobe and thalamic infarction.
4.Impact of stenting at the origin of vertebral artery on cognitive function in patients with first-onset temporal or thalamic infarction
Yaozhi HU ; Shanshan CUI ; Ligong ZHANG ; Linzhi GAO
Journal of Clinical Medicine in Practice 2024;28(13):67-71
Objective To investigate the impact of stenting at the origin of vertebral artery(VAO)on cognitive function in patients with first-onset temporal or thalamic infarction.Methods A total of 65 patients with first-onset temporal or thalamic infarction were selected as research subjects,and were diagnosed with new-onset infarction in the medial temporal lobe or thalamus by craniocere-bral magnetic resonance imaging(MRI),and severe stenosis of VAO as the responsible vessel for in-farction was confirmed by head and neck computed tomography angiography(CTA).A total of 35 pa-tients who received VAO stenting were included in the stenting group,and 30 patients who received drug-based conservative treatment were included in the control group.The Montreal Cognitive Assess-ment Scale(MoCA),Wechsler Adult Intelligence Scale-Digit Span Test(WAIS-DS),and Fuld Ob-ject Memory Evaluation Scale(FOM)scores were compared between the two groups before treatment,14 days and 3 months after treatment.Results Before treatment,there was no significant difference in the scores of each scale between the two groups(P>0.05).At 14 days and 3 months after treat-ment,the total MoCA score and the scores of visual space and executive function,delayed recall,and language dimension in the stenting group were higher than those in the control group(P<0.05).The FOM score in the stenting group was higher than that in the control group at 3 months after treat-ment(P<0.05).Conclusion Stenting can significantly improve the cognitive function of patients with temporal lobe and thalamic infarction.
5.Paraneoplastic limbic encephalitis with double positive anti-Hu and Yo antibodies: a case report
Yanlei GENG ; Jinbo CHEN ; He MA ; Hongliang CHEN ; Xiaowen SONG ; Hong LI ; Shujun LU ; Yipeng SU ; Yaozhi HU ; Cong LI ; Xuechuan GENG
Chinese Journal of Neurology 2019;52(5):406-409
Paraneoplastic neurological syndromes (PNS) are a rare group of immune-mediated disorders that affect the central and peripheral neuromuscular system in association with cancer.If the limbal lobe system of the brain is involved,it will show paraneoplastic limbal encephalitis(PLE).The discern of patients with PNS is challenging since tumors causing paraneoplastic neurologic disorders are often asymptomatic and sometimes occult.We report a case of PLE with double positive anti-Hu and Yo antibodies,and further analyze and discuss it in conmbination with relevant literature to improve the understanding of the disease.